Sanofi Reports Q3 Earnings Beat; Raises FY22 EPS Guidance

23
1
Favorite

Sanofi Reports Q3 Earnings Beat; Raises FY22 EPS Guidance

Seeking Alpha2022-10-28

Sanofi Q3 Non-GAAP EPS of €2.88 beats by €0.22.
Revenue of €12.48B (+19.7% Y/Y) beats by €440M, sales growth of 9.0% at CER driven by Specialty Care and Vaccines.
Specialty Care grew 19.9% driven by Dupixent® performance (€2,314M, +44.5%) and launch momentum in Rare Disease.
Vaccines up 23.5% from strong Flu sales in the quarter, rebound of Travel vaccines and growth of Meningitis and PPH franchises.
General Medicines achieved 2.4% core assets growth despite lower Lovenox® sales due to decreasing demand from COVID-19.
CHC up 1.9% with strong growth in Digestive Wellness and Cough & Cold in a normalizing market environment post-COVID-19.
Full-year 2022 business EPS guidance revise upward: Sanofi now expects 2022 business EPS to grow ~16% at CER, barring unforeseen major adverse events.
Applying average October 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated between +9.5% to +10.5%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

DarkFate
·2022-10-28
Like
Reply
Like
Report

抱歉，当前请求异常(-1)

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1141353899?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2022-10-28 13:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141353899","market":"us","top_or_hot":-1,"title":"Sanofi Reports Q3 Earnings Beat; Raises FY22 EPS Guidance","media":"Seeking Alpha","content":"<html><head></head><body><ul><li>Sanofi Q3 Non-GAAP EPS of €2.88 beats by €0.22.</li><li>Revenue of €12.48B (+19.7% Y/Y) beats by €440M, sales growth of 9.0% at CER driven by Specialty Care and Vaccines.</li><li>Specialty Care grew 19.9% driven by Dupixent® performance (€2,314M, +44.5%) and launch momentum in Rare Disease.</li><li>Vaccines up 23.5% from strong Flu sales in the quarter, rebound of Travel vaccines and growth of Meningitis and PPH franchises.</li><li>General Medicines achieved 2.4% core assets growth despite lower Lovenox® sales due to decreasing demand from COVID-19.</li><li>CHC up 1.9% with strong growth in Digestive Wellness and Cough &amp; Cold in a normalizing market environment post-COVID-19.</li><li><b>Full-year 2022 business EPS guidance revise upward</b>: Sanofi now expects 2022 business EPS to grow ~16% at CER, barring unforeseen major adverse events.</li><li>Applying average October 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated between +9.5% to +10.5%.</li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Reports Q3 Earnings Beat; Raises FY22 EPS Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Reports Q3 Earnings Beat; Raises FY22 EPS Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 13:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3897034-sanofi-reports-q3-earnings-beat-raises-fy22-eps-guidance><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofi Q3 Non-GAAP EPS of €2.88 beats by €0.22.Revenue of €12.48B (+19.7% Y/Y) beats by €440M, sales growth of 9.0% at CER driven by Specialty Care and Vaccines.Specialty Care grew 19.9% driven by ...</p>\n\n<a href=\"https://seekingalpha.com/news/3897034-sanofi-reports-q3-earnings-beat-raises-fy22-eps-guidance\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNY","symbol_name":"赛诺菲安万特","start_time":0,"source_url":"https://seekingalpha.com/news/3897034-sanofi-reports-q3-earnings-beat-raises-fy22-eps-guidance","article_id":"1141353899","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141353899","pubTimestamp":1666936522,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Sanofi Q3 Non-GAAP EPS of €2.88 beats by €0.22.Revenue of €12.48B (+19.7% Y/Y) beats by €440M, sales","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNY":"赛诺菲安万特"},"translate_title":"赛诺菲报告第三季度收益超过预期；提高2012财年每股收益指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":0.9},"content_text":"Sanofi Q3 Non-GAAP EPS of €2.88 beats by €0.22.Revenue of €12.48B (+19.7% Y/Y) beats by €440M, sales growth of 9.0% at CER driven by Specialty Care and Vaccines.Specialty Care grew 19.9% driven by Dupixent® performance (€2,314M, +44.5%) and launch momentum in Rare Disease.Vaccines up 23.5% from strong Flu sales in the quarter, rebound of Travel vaccines and growth of Meningitis and PPH franchises.General Medicines achieved 2.4% core assets growth despite lower Lovenox® sales due to decreasing demand from COVID-19.CHC up 1.9% with strong growth in Digestive Wellness and Cough & Cold in a normalizing market environment post-COVID-19.Full-year 2022 business EPS guidance revise upward: Sanofi now expects 2022 business EPS to grow ~16% at CER, barring unforeseen major adverse events.Applying average October 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated between +9.5% to +10.5%.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9986633494,"gmtCreate":1666936790319,"gmtModify":1676537835002,"author":{"id":"4097476142152970","authorId":"4097476142152970","name":"DarkFate","avatar":"https://static.tigerbbs.com/a22f6ff84fe185b6d3ad31b8673302d8","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"4097476142152970","authorIdStr":"4097476142152970"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986633494","repostId":1141353899,"repostType":4,"repost":{"id":"1141353899","kind":"news","pubTimestamp":1666936522,"share":"https://ttm.financial/m/news/1141353899?lang=&edition=full_marsco","pubTime":"2022-10-28 13:55","market":"us","language":"en","title":"Sanofi Reports Q3 Earnings Beat; Raises FY22 EPS Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1141353899","media":"Seeking Alpha","summary":"Sanofi Q3 Non-GAAP EPS of €2.88 beats by €0.22.Revenue of €12.48B (+19.7% Y/Y) beats by €440M, sales","content":"<html><head></head><body><ul><li>Sanofi Q3 Non-GAAP EPS of €2.88 beats by €0.22.</li><li>Revenue of €12.48B (+19.7% Y/Y) beats by €440M, sales growth of 9.0% at CER driven by Specialty Care and Vaccines.</li><li>Specialty Care grew 19.9% driven by Dupixent® performance (€2,314M, +44.5%) and launch momentum in Rare Disease.</li><li>Vaccines up 23.5% from strong Flu sales in the quarter, rebound of Travel vaccines and growth of Meningitis and PPH franchises.</li><li>General Medicines achieved 2.4% core assets growth despite lower Lovenox® sales due to decreasing demand from COVID-19.</li><li>CHC up 1.9% with strong growth in Digestive Wellness and Cough &amp; Cold in a normalizing market environment post-COVID-19.</li><li><b>Full-year 2022 business EPS guidance revise upward</b>: Sanofi now expects 2022 business EPS to grow ~16% at CER, barring unforeseen major adverse events.</li><li>Applying average October 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated between +9.5% to +10.5%.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Reports Q3 Earnings Beat; Raises FY22 EPS Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Reports Q3 Earnings Beat; Raises FY22 EPS Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-28 13:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3897034-sanofi-reports-q3-earnings-beat-raises-fy22-eps-guidance><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofi Q3 Non-GAAP EPS of €2.88 beats by €0.22.Revenue of €12.48B (+19.7% Y/Y) beats by €440M, sales growth of 9.0% at CER driven by Specialty Care and Vaccines.Specialty Care grew 19.9% driven by ...</p>\n\n<a href=\"https://seekingalpha.com/news/3897034-sanofi-reports-q3-earnings-beat-raises-fy22-eps-guidance\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNY":"赛诺菲安万特"},"source_url":"https://seekingalpha.com/news/3897034-sanofi-reports-q3-earnings-beat-raises-fy22-eps-guidance","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141353899","content_text":"Sanofi Q3 Non-GAAP EPS of €2.88 beats by €0.22.Revenue of €12.48B (+19.7% Y/Y) beats by €440M, sales growth of 9.0% at CER driven by Specialty Care and Vaccines.Specialty Care grew 19.9% driven by Dupixent® performance (€2,314M, +44.5%) and launch momentum in Rare Disease.Vaccines up 23.5% from strong Flu sales in the quarter, rebound of Travel vaccines and growth of Meningitis and PPH franchises.General Medicines achieved 2.4% core assets growth despite lower Lovenox® sales due to decreasing demand from COVID-19.CHC up 1.9% with strong growth in Digestive Wellness and Cough & Cold in a normalizing market environment post-COVID-19.Full-year 2022 business EPS guidance revise upward: Sanofi now expects 2022 business EPS to grow ~16% at CER, barring unforeseen major adverse events.Applying average October 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated between +9.5% to +10.5%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":23,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}